British Journal of Pharmaceutical Research, ISSN: 2231-2919,Vol.: 7, Issue.: 6
mAb Higher Order Structure Analysis with Protein Conformational Array ELISA
Michael Davies1, Gan Wang2, Guofeng Fu1 and Xing Wang1* 1Array Bridge Inc., 4320 Forest Park Avenue, Suite 303, St. Louis, MO 63108, USA. 2Institute of Environmental Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI 48201, USA.
Michael Davies1, Gan Wang2, Guofeng Fu1 and Xing Wang1*
1Array Bridge Inc., 4320 Forest Park Avenue, Suite 303, St. Louis, MO 63108, USA.
2Institute of Environmental Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI 48201, USA.
(1) Jinyong Peng, College of Pharmacy, Dalian Medical University, Dalian, China.
(2) Syed A. A. Rizvi, Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, USA.
(1) Anonymous, DIT University, India.
(2) Anonymous, Wrocław Medical University, Poland.
(3) Anonymous, Shanghai Jiao Tong University, China.
(4) Anonymous, Canada.
Complete Peer review History: http://sciencedomain.org/review-history/10141
The clinical and biological properties of protein-based therapeutics, or biologics, are closely related to their Higher Order Structures (HOS) which in turn can be altered by many physical and chemical conditions. A novel technology to monitor changes in monoclonal antibody (mAb) HOS is the Protein Conformational Array (PCA) ELISA which uses a bank of more than 30 antibodies to measure protein epitope change on the surface of the mAb. Using this technology, this report provided interesting findings for the first time on the HOS changes in response to the various conditions often encountered during mAb formulation development. Specifically, one IgG1 and four IgG2 native molecules in formulation buffer were compared with the same IgG which had undergone exposure to increased temperature, pH extremes and light exposure. In addition, we also examined the impact of glycation and de-glycosylation on the mAb HOS. This study demonstrated that the PCA ELISA is stability-indicating and can provide detailed HOS information that could be important for the successful development of monoclonal antibodies.
Formulation development; monoclonal antibody; higher order structure; protein conformational array ELISA (PCA ELISA); conformational impurity.
Full Article - PDF Page 401-412
DOI : 10.9734/BJPR/2015/18952Review History Comments